Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Sunny Pharmtech Inc. (6676:TWSE), powered by AI.
Sunny Pharmtech Inc. is currently trading at $12.95. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Sunny Pharmtech Inc. on Alpha Lenz.
Sunny Pharmtech Inc.'s P/E ratio is -12.3.
“Sunny Pharmtech Inc. trades at a P/E of -12.3 (undervalued) with modest ROE of -13.9%. 3Y revenue CAGR of 20.2% highlights clear growth momentum.”
Ask for details →Sunny Pharmtech Inc. is a specialty pharmaceutical company focused on the research, development, manufacturing, and sale of novel and generic drugs. Headquartered in Taoyuan, Taiwan, the company addresses unmet medical needs across Taiwan, the United States, and global markets. Sunny Pharmtech’s core strengths lie in high-value, complex generics and niche therapeutics, particularly within oncology, immunology, and cardiovascular medicine. The company’s product portfolio includes anesthetic ointments, vitamin B12 injections, anti-infective capsules, and treatments for blood disorders, among other advanced therapeutics. Leveraging in-house API development, cutting-edge technologies, and adherence to international quality standards, Sunny Pharmtech offers integrated solutions from drug formulation to commercial manufacturing. Its operations serve both as a pharmaceutical innovator and a contract development and manufacturing organization (CDMO), supporting global partners with process development and regulatory submissions. This positioning underscores the firm's significance in providing innovative, reliable, and accessible healthcare solutions to a diverse, international patient base.
“Sunny Pharmtech Inc. trades at a P/E of -12.3 (undervalued) with modest ROE of -13.9%. 3Y revenue CAGR of 20.2% highlights clear growth momentum.”
Ask for details →Sunny Pharmtech Inc. (ticker: 6676) is a company listed on TWSE in the Healthcare sector (Biotechnology). It has approximately 158 employees. Market cap is $1.9B.
The current price is 12.95 with a P/E ratio of -12.35x and P/B of 1.84x.
ROE is -13.89% and operating margin is -38.99%. Annual revenue is $418M.